8-K: NovaBay Auditor Declines Re-appointment Amid Dissolution Plans

NovaBay Pharmaceuticals announces its long-standing auditor, WithumSmith+Brown, PC, will not stand for re-appointment as the company pursues dissolution.

Summary

• WithumSmith+Brown, PC (Withum) notified NovaBay Pharmaceuticals, Inc. on January 22, 2026, that they are declining to stand for re-appointment as the company's independent registered public accounting firm for the fiscal year ending December 31, 2025.
• Withum had served as the company's independent registered public accounting firm since 2010.
• Withum's audit reports on the company's consolidated financial statements for the fiscal years ended December 31, 2024, and 2023, did not contain any adverse opinion or disclaimer of opinion and were not qualified or modified, except for an explanatory paragraph regarding the company seeking stockholder approval to dissolve and distribute all remaining assets.
• During the two most recent fiscal years (2024 and 2023) and the subsequent interim period, there were no disagreements on accounting principles, financial statement disclosure, or auditing scope or procedure between the company and Withum.
• There were also no reportable events within the meaning of Item 304(a)(1)(v) of Regulation S-K during the specified periods.
• The company has authorized Withum to respond fully to inquiries from the successor independent registered public accounting firm.
• The company is currently in the process of identifying and engaging a new independent registered public accounting firm and will disclose the engagement once finalized.
• WithumSmith+Brown, PC confirmed agreement with the statements made by NovaBay Pharmaceuticals, Inc. in the Form 8-K regarding their firm.

Sentiment

Score: 2

Explanation: The auditor's decision not to stand for re-appointment, explicitly linked to the company's plan to dissolve and distribute assets, indicates a highly negative outlook for the company's future operations and shareholder value.

Positives

• No disagreements on accounting principles, financial statement disclosure, or auditing scope or procedure were reported between the Company and Withum during the past two fiscal years and subsequent interim period.
• No reportable events occurred during the two most recent fiscal years (2024, 2023) and the subsequent interim period through the date of this Current Report on Form 8-K.

Negatives

• The company's long-standing independent auditor, WithumSmith+Brown, PC, declined to stand for re-appointment for the fiscal year ending December 31, 2025.
• Withum's previous audit reports included an explanatory paragraph noting the company was seeking stockholder approval to dissolve and distribute assets, indicating a potential cessation of operations.

Risks

• The company is seeking approval from its stockholders to dissolve and distribute all remaining assets to stockholders, indicating a high risk of operational cessation and liquidation.
• Uncertainty exists regarding the identification and engagement of a new independent registered public accounting firm, which is complicated by the company's stated intent to dissolve.

Future Outlook

The company is seeking stockholder approval to dissolve and distribute all remaining assets, indicating a future cessation of operations. Management is also in the process of identifying and engaging a new independent registered public accounting firm.

Management Comments

• The Company is in the process of identifying and engaging a new independent registered public accounting firm and will disclose the engagement of a new auditor once finalized.

Industry Context

Auditor changes are a routine part of corporate governance, but when an auditor declines re-appointment, especially in the context of a company seeking dissolution, it signals significant operational and strategic shifts. This event highlights the company's move towards winding down operations, a trend sometimes seen in smaller pharmaceutical companies facing market challenges or strategic realignments.

Comparison to Industry Standards

• NA

Corporate Governance

Stakeholder Impact

• Shareholders: Direct impact due to the company's plan to dissolve and distribute assets, implying a liquidation event and potential return of capital.
• Employees: Potential job losses as the company moves towards dissolution and cessation of operations.
• Creditors: Implications for repayment depending on the dissolution process and asset distribution.

Next Steps

• Identify and engage a new independent registered public accounting firm.
• Disclose the engagement of the new auditor once finalized.
• Seek stockholder approval to dissolve and distribute all remaining assets.

Key Dates

Recommendation

The company's independent auditor declining re-appointment, explicitly citing the company's plan to dissolve and distribute assets to stockholders, signals an imminent cessation of operations and liquidation. This event fundamentally alters the investment thesis, indicating a high probability of significant capital loss for current shareholders as the company winds down.

Keywords

NovaBay Pharmaceuticals, NBY, auditor change, accounting firm, dissolution, liquidation, SEC filing, 8-K, corporate governance